Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0T8MA
|
||||
Former ID |
DIB005567
|
||||
Drug Name |
ATN-224
|
||||
Synonyms |
Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 2 | [1] | ||
Company |
University of Michigan
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C10H30MoN2O2S4
|
||||
Canonical SMILES |
S=[Mo-2](=S)(=S)=S.C[N+](C)(CCO)C.C[N+](C)(CCO)C
|
||||
CAS Number |
CAS 649749-10-0
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Superoxide dismutase [Cu-Zn] | Target Info | Inhibitor | [2] | |
BioCyc Pathway | Reactive oxygen species degradation | ||||
KEGG Pathway | Peroxisome | ||||
Amyotrophic lateral sclerosis (ALS) | |||||
Huntington's disease | |||||
Prion diseases | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
FOXA1 transcription factor network | |||||
PathWhiz Pathway | Degradation of Superoxides | ||||
Reactome | Platelet degranulation | ||||
Detoxification of Reactive Oxygen Species | |||||
WikiPathways | Oxidative Stress | ||||
Copper homeostasis | |||||
Detoxification of Reactive Oxygen Species | |||||
Nifedipine Activity | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Dopamine metabolism | |||||
AGE/RAGE pathway | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health. | ||||
REF 2 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.